The Gynecologic Oncology Group
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gog.org
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
- Conditions
- Endometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaStage IA Uterine Corpus Cancer AJCC v7Stage IB Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7Stage II Uterine Corpus Cancer AJCC v7Stage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7
- Interventions
- Radiation: Internal Radiation TherapyOther: Quality-of-Life AssessmentRadiation: Radiation Therapy
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 813
- Registration Number
- NCT00942357
- Locations
- 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Undifferentiated Ovarian CarcinomaOvarian Brenner TumorOvarian Serous CystadenocarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian CarcinomaOvarian Clear Cell CystadenocarcinomaFallopian Tube CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Endometrioid AdenocarcinomaOvarian Mucinous Cystadenocarcinoma
- Interventions
- Biological: Urokinase-Derived Peptide A6Other: Laboratory Biomarker Analysis
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00939809
- Locations
- 🇺🇸
Georgia Regents University Medical Center, Augusta, Georgia, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Stony Brook University Medical Center, Stony Brook, New York, United States
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
- Conditions
- Cervical CancerPrecancerous Condition
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2010-11-07
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 55
- Registration Number
- NCT00898144
Collecting Tumor Samples From Patients With Gynecological Tumors
- Conditions
- Cervical Small Cell CarcinomaEndometrioid Stromal SarcomaOvarian Serous CystadenocarcinomaRecurrent Cervical CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Uterine Corpus CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage I Ovarian Cancer
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 275
- Registration Number
- NCT00897442
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
- Conditions
- brca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 10000
- Registration Number
- NCT00897455
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
- Conditions
- Vulvar Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00898352
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
- Conditions
- Malignant Ovarian NeoplasmMalignant Ovarian Transitional Cell TumorStage IIIA Ovarian CancerFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous AdenocarcinomaMalignant Ovarian Brenner TumorMalignant Ovarian Mixed Epithelial TumorFallopian Tube Clear Cell AdenocarcinomaMalignant Ovarian Mucinous TumorOvarian Adenocarcinoma
- Interventions
- Other: Cytology Specimen Collection ProcedureOther: Laboratory Biomarker Analysis
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 2500
- Registration Number
- NCT00899093
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Mercy Hospital Springfield, Springfield, Missouri, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
- Conditions
- BRCA1 Mutation CarrierBRCA2 Mutation CarrierBreast Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00899145
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Transitional Cell CarcinomaRecurrent Uterine Corpus CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Undifferentiated CarcinomaEndometrial Adenocarcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT00888173
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
- Conditions
- Stage IC Ovarian CancerStage IB Fallopian Tube CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Primary Peritoneal CancerStage IA Fallopian Tube CancerStage IC Fallopian Tube CancerStage IIB Fallopian Tube CancerStage IIIC Ovarian CancerStage IA Ovarian Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Polyvalent Antigen-KLH Conjugate VaccineBiological: Saponin-based Immunoadjuvant OBI-821
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 171
- Registration Number
- NCT00857545
- Locations
- 🇺🇸
Gynecologic Oncology of West Michigan PLLC, Grand Rapids, Michigan, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States